University of Texas: CD19 CAR NK-Cell Therapy Achieves 73% Response Rate in Patients With Leukemia, Lymphoma
February 07, 2020
February 07, 2020
HOUSTON, Texas, Feb. 7 [TNSmedicalresearch] -- The University of Texas's MD Anderson Cancer Center issued the following news release on Feb. 5:
* * *
- MD Anderson-developed cell therapy results in no major toxicities in Phase I/IIa trial for relapsed and refractory hematologic cancers
* * *
According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen rece . . .
* * *
- MD Anderson-developed cell therapy results in no major toxicities in Phase I/IIa trial for relapsed and refractory hematologic cancers
* * *
According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen rece . . .